The effect of intensive lipid lowering on coronary atheroma and clinical outcome

Heart

Volumn 93, Issue 2, 2007, Pages 149-151

  Houslay, Emma S ^a   Sarma, Jaydeep ^a   Uren, Neal G ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; COLONY STIMULATING FACTOR 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG EFFECT; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33846577819     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.105676     Document Type: Review

References (22)

1. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998;32:140-6.
4. Lipid Study Group. Prevention of cardiovascular events and death wirh pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349- 57.
5. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285(13): 1711-8.
6. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
7. Wiviott SD, Cannon CP, Morrow DA, et al, for the PROVE IT-TIMI 22 investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy. J Am Coll Cardiol 2005;46:1411-16.
8. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowerinq disease management clinics: the ALLIANCE study. J Am Coll Cardiol 2004;44:1772-9.
9. LaRosa JC, Grundy S, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
10. Pedersen TR, Faegeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study. JAMA 2005;294:2437-45.
11. Newman C, Tsai J, Szarek M, et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006;97:61-7.
12. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17.
13. Corti R, Fuster V, Fayad ZA, et al. Effects of aggressive versus conventional lipid-lowerinq therapy by simvastatin on human atherosclerotic lesions. J Am Coll Cardiol 2005;46:106-12.
14. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80.
15. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity stafin therapy on regression of coronary atherosclerosis (ASTEROID). JAMA 2005;295:1556-65.
16. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-19.
17. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-83.
18. Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996;94:874-7.
19. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
20. Ridker PM, Haughie P. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J Investig Med 1998;46:391-5.
21. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-44.
22. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1015- 22.